[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356531-105":59,"doc-detail-356531-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-and-functional-platelet-abnormalities-in-myeloproliferative-neoplasms","Molecular and Functional Platelet Abnormalities in Myeloproliferative Neoplasms","","Blood platelets arise from megakaryocytes and perform roles beyond hemostasis, including inflammation, immunity, and cancer-related processes. Myeloproliferative neoplasms (MPNs) are clonal stem-cell disorders driven by somatic mutations that activate JAK-STAT signaling and cause excessive myeloid proliferation. Thrombosis occurs in about one-fifth of patients at diagnosis and persists across disease stages, while bleeding can coexist, complicating clinical care. This review explains how circulating platelets reflect MPN pathophysiology through molecular and functional abnormalities, and summarizes platelet transcriptomics, proteomics, and candidate biomarkers. Insights are framed to complement diagnostic and prognostic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-and-functional-platelet-abnormalities-in-myeloproliferative-neoplasms/356531/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-and-functional-platelet-abnormalities-in-myeloproliferative-neoplasms/356531.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do myeloproliferative neoplasms (MPNs) drive abnormal platelet-related disease?","Question",{"text":112,"@type":113},"MPNs are clonal stem-cell disorders caused by mutations that activate JAK-STAT signaling, leading to excessive myeloid production. The same clonal changes in megakaryocytes can create inherited platelet molecular abnormalities that contribute to hemostatic imbalance and risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is thrombosis a major issue in MPNs, even when bleeding can also occur?",{"text":117,"@type":113},"Thrombosis affects roughly one-fifth of patients at diagnosis and stays elevated through the disease course. A paradoxical coexistence of bleeding further complicates management by reflecting both prothrombotic and impaired hemostatic responsiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What approaches does the review discuss for identifying platelet biomarkers in MPNs?",{"text":121,"@type":113},"The review highlights platelet transcriptomics and proteomics to discover disease-specific signatures. It also emphasizes emerging platelet-associated candidates as dynamic biomarkers for marrow niche pathology and for thrombotic and bleeding risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356531,1790668166,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nMolecular and Functional Platelet Abnormalities in Myeloproliferative Neoplasms  \nAnn X. Wang , Belinda B. Guo  and Matthew D. Linden *  \nAcademic Editors: Stepan Gambaryan and Mikhail A. Panteleev  \nReceived: 20 February 2026  \nRevised: 16 March 2026  \nAccepted: 18 March 2026  \nPublished: 19 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nSchool of Biomedical Science, University of Western Australia, Perth, WA 6009, Australia  \n* [Correspondence: matthew.linden@uwa.edu.au](Correspondence: matthew.linden@uwa.edu.au)  \nAbstract  \nBlood platelets are derived from megakaryocytes with functions extending beyond hemostasis to inflammation, immunity, and cancer. Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders driven by somatic mutations affecting JAK-STAT signaling, leading to excessive myeloid proliferation. Thrombosis affects approximately one-fifth of patients at diagnosis and remains elevated throughout the disease course, while the paradoxical coexistence of bleeding further complicates clinical management. In addition, MPNs may progress to advanced disease stages, including bone marrow fibrosis and transformation to acute myeloid leukemia, leading to ineffective hematopoiesis, worsening symptom burden, and poor clinical outcomes. This review outlines how peripherally circulating platelets provide a unique window into MPN pathophysiology, with emphasis on their functional and molecular abnormalities. We summarize current understanding of platelet-mediated hemostatic imbalance across MPN subtypes. We discuss the potential of platelet transcriptomics and proteomics to reveal disease-specific signatures. We further highlight emerging platelet-associated candidates with potential utility as dynamic biomarkers for both the pathological marrow niche and thrombotic and bleeding risk. Together, these insights underscore the potential of platelet-based approaches to complement existing diagnostic and prognostic strategies in MPNs.  \nKeywords: platelets; myeloproliferative neoplasms; myelofibrosis; megakaryocytes; platelet function; platelet transcriptome; platelet proteome; thrombosis; hemostasis; biomarker  \n1. Introduction  \nPlatelets are best known for their essential role in maintaining vascular integrity and mediating hemostasis [1] . Beyond these classical functions, platelets have been extensively studied in solid tumors for their contributions to immune evasion, angiogenesis, and metastasis [1] . More recently, growing evidence has extended their involvement into hematological malignancies.  \nMyeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by the excessive production of mature myeloid cells, driven predominantly by mutations in JAK2, CALR, or MPL that constitutively activate the JAK-STAT pathway [2] . The classical MPN subtypes include polycythemia vera (PV), essential thrombocythemia (ET), pre-fibrotic myelofibrosis, and primary myelofibrosis (PMF) [3] . Across all MPNs, hemostatic complications affect approximately 20% of patients and represent a major cause of early morbidity and mortality [4–7] . Progression to advanced disease stages, including myelofibrosis (MF) and acute myeloid leukemia (AML), occurs in roughly 5–20%  \ndepending on disease subtype and duration and is associated with increased disease burden and reduced survival [4,8,9] .  \nAs a consequence of oncogenic signaling-driven myeloproliferation, platelet overproduction is a defining feature of ET, while PV is characterized primarily by erythrocytosis with concomitant megakaryocytic hyperplasia and increased platelet output [10] . MF is marked by bone marrow (BM) architectural disruption and ineffective hematopoiesis, in which platelet counts are more heterogeneous and may decline with disease progression, often accompan","cbCaickNX7cgHJjR","https://ap.wps.com/l/cbCaickNX7cgHJjR","pdf",988270,15,"English","# Abstract\n# 1. Introduction","[{\"question\":\"How do myeloproliferative neoplasms (MPNs) drive abnormal platelet-related disease?\",\"answer\":\"MPNs are clonal stem-cell disorders caused by mutations that activate JAK-STAT signaling, leading to excessive myeloid production. The same clonal changes in megakaryocytes can create inherited platelet molecular abnormalities that contribute to hemostatic imbalance and risk.\"},{\"question\":\"Why is thrombosis a major issue in MPNs, even when bleeding can also occur?\",\"answer\":\"Thrombosis affects roughly one-fifth of patients at diagnosis and stays elevated through the disease course. A paradoxical coexistence of bleeding further complicates management by reflecting both prothrombotic and impaired hemostatic responsiveness.\"},{\"question\":\"What approaches does the review discuss for identifying platelet biomarkers in MPNs?\",\"answer\":\"The review highlights platelet transcriptomics and proteomics to discover disease-specific signatures. It also emphasizes emerging platelet-associated candidates as dynamic biomarkers for marrow niche pathology and for thrombotic and bleeding risk.\"}]","Molecular and Functional Platelet Abnormalities in Myeloproliferative Neoplasms | PDF",1790125865,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b920d67abb6f5e1e41139e8023a24016.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8626ed64a885d5edfec89508916e0002.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be914f6f0c06fac63b52976a8912ed01.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cc4d7e40e560811c4ed47dbcd6a095d.webp",980,1385]